<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810481</url>
  </required_header>
  <id_info>
    <org_study_id>MDT20032BTIGER</org_study_id>
    <nct_id>NCT04810481</nct_id>
  </id_info>
  <brief_title>Bispectral Index and End-Tidal Anesthetic Gas Concentration in Pediatric Patients</brief_title>
  <acronym>BTIGER</acronym>
  <official_title>Bispectral Index and End-Tidal Anesthetic Gas Concentration in Pediatric Patients Undergoing Sevoflurane Anesthesia (BTIGER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the relationship between BIS™ values including&#xD;
      EEG profile and anesthetic agents in the pediatric population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, observational, non-invasive, randomized controlled study&#xD;
      to collect data to compare the performance of standard practice (SP) group with the BIS™&#xD;
      monitoring (BIS) group. Pediatric patients between the ages of 4 to 18 years undergoing&#xD;
      routine sevoflurane general anesthesia with an expected surgical procedure duration of&#xD;
      greater than 30 minutes will be recruited. If the surgery is less than 15 minutes, the data&#xD;
      will continue to be collected, but will not be included in the data analysis and the subject&#xD;
      will be replaced with an additional subject. General surgeries including abdominal,&#xD;
      urological, orthopedic, or ophthalmological procedures with an American Society of&#xD;
      Anesthesiologists physical status of I - III.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Investigator will be blinded to the BIS value in the Standard Practice Group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>BIS performance</measure>
    <time_frame>duration of anesthesia administration</time_frame>
    <description>To report the BIS range of values (0-100) with sevoflurane in pediatric patients ages 4 to 18 years. The BIS values from each group will be reported to show that the values are similar in the BIS group when compared to the Standard Practice Group. The BIS value correlates to the depth of anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery Assessments</measure>
    <time_frame>up to 4 hours following anesthesia administration</time_frame>
    <description>Secondary endpoint(s):&#xD;
Recovery assessments in patients receiving monitoring compared to standard anesthetic practice (instructions for collection contained in Study Procedures and Assessments):&#xD;
Emergence, defined as the time when any of the following first occurred:&#xD;
Eyes open spontaneously&#xD;
Crying or phonating&#xD;
Purposeful movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Aldrete Score</measure>
    <time_frame>up to 4 hours following anesthesia administration</time_frame>
    <description>The Modified Aldrete Score assesses the readiness of the subject to be discharged from the PACU with the higher the number correlating to the more ready a patient is to be discharged, the score range is 0-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthesia Airway Management</measure>
    <time_frame>up to 4 hours following anesthesia administration</time_frame>
    <description>Awake and Deep Extubation (endotracheal tube vs. laryngeal mask airway&#xD;
Airway reflexes (e.g., coughing, choking, laryngospasm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Anesthesia Assessment</measure>
    <time_frame>up to 4 hours following anesthesia administration</time_frame>
    <description>recorded as the incidence of movements, grimacing, eye opening, tearing, sweating, mydriasis and cardiovascular changes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Standard Practice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Anesthesia will be provided at the discretion of the anesthesiologist following cardiovascular variables in accordance with usual clinical indications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIS Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthesia will be titrated to achieve a BIS value of 45-60 during maintenance of anesthesia. Additional intervention will be provided only if the subject is in distress.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIS Complete Monitoring System</intervention_name>
    <description>The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BISx™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.</description>
    <arm_group_label>BIS Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric Subjects (ASA PS I or II or III) aged: 4 years to 18 years scheduled for&#xD;
             procedures with sedation where the process of assessment will not interfere with the&#xD;
             procedure, progress, or patient care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has severe contact allergies that may cause a reaction to standard adhesive materials&#xD;
             found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes, or&#xD;
             other medical sensors&#xD;
&#xD;
          -  Known neurological disorder (e.g., epilepsy, the presence of a brain tumor, a history&#xD;
             of brain surgery, hydrocephalic disorders, depression needing treatment with&#xD;
             anti-depressive drugs, a history of brain trauma, hemiplegia, demyelinating disorders,&#xD;
             cerebral palsy, congenital anomalies of the brain or spinal cord, or other known&#xD;
             neurologic disorders)&#xD;
&#xD;
          -  Severe developmental delay per assessment of investigator or report of parent/guardian&#xD;
&#xD;
          -  Airway abnormalities&#xD;
&#xD;
          -  Pregnancy; subjects of childbearing potential will have a urine screen for pregnancy&#xD;
             before surgery&#xD;
&#xD;
          -  If the process of assessment will interfere with the procedure or the progress of the&#xD;
             procedure&#xD;
&#xD;
          -  Taking psychoactive medications&#xD;
&#xD;
          -  Taking any medications that may have an impact on the Central Nervous System (CNS)&#xD;
&#xD;
          -  Planned use of any regional anesthesia; a local field block is not included in this&#xD;
             exclusion and can be used at the discretion of the anesthesia provider&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ami Stuart, PhD</last_name>
    <phone>801-793-4800</phone>
    <email>ami.stuart@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Monza, BS</last_name>
    <phone>303-763-0813</phone>
    <email>stephanie.r.monza@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Safon</last_name>
      <email>Rebecca.Safon@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Richard Ing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen VantHof</last_name>
      <email>KVantHof@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Eric Cheon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Sweeney, BSN</last_name>
      <phone>919-681-6221</phone>
      <email>katherine.sweeney@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Brad Taicher, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center, Children's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Fierro, BS</last_name>
      <email>Marco.Fierro@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Gijo Alex, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

